These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19514925)

  • 1. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab-induced cutaneous toxicity.
    Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
    Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
    Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
    J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acneiform eruption induced by cetuximab.
    Cotena C; Gisondi P; Colato C; Girolomoni G
    Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
    Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
    Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S; Gonella S; Alessandra B; Palese A
    Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
    Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
    Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Unilateral acneiform rash in facial palsy].
    Kerob D; Hennequin V; Bousquet G; Behm E; Lebbe C
    Ann Dermatol Venereol; 2010 Nov; 137(11):727-9. PubMed ID: 21074658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
    Saif MW; Longo WL; Israel G
    Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
    Bauman JE; Eaton KD; Martins RG
    Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab: adverse event profile and recommendations for toxicity management.
    Thomas M
    Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grover's disease induced by cetuximab.
    Tscharner GG; Bühler S; Borner M; Hunziker T
    Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
    Acevedo-Henao CM; Valette G; Miglierini P; Lefur E; Pradier O
    Cancer Radiother; 2012 Oct; 16(7):601-3. PubMed ID: 23089070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab.
    Roman J; Dissaux G; Gouillou M; Gobel Y; Potard G; Leclere JC; Conan-Charlet V; Gujral D; Abgral R; Guibourg B; Pradier O; Schick U
    Target Oncol; 2017 Aug; 12(4):505-512. PubMed ID: 28580506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
    Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
    Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.